Skip to content

CAPRICOR THERAPEUTICS, INC.: 10-Q filed 2021-11-12

What CAPRICOR THERAPEUTICS, INC. reported in its quarterly report filed 2021-11-12 (fiscal Q3 2021): 37 published measures, 109 facts as tagged in accession 0001558370-21-015571.

This filing

Form
10-Q (quarterly report)
Filed
2021-11-12
Fiscal period
fiscal Q3 2021
Accession
0001558370-21-015571 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CAPRICOR THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-3043,100,521USD
At 2020-12-3134,618,796USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-09-306,364,551USD
At 2020-12-316,419,012USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-3036,735,970USD
At 2021-06-3033,380,130USD
At 2021-03-3136,380,785USD
At 2020-12-3128,199,784USD
At 2020-09-3030,407,919USD
At 2020-06-3031,653,954USD
At 2020-03-319,592,634USD
At 2019-12-316,839,386USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-09-3040,839,158USD
At 2020-12-3132,665,874USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,931,807USD92
2021-01-01 to 2021-09-30-13,831,996USD273
2021-04-01 to 2021-06-30-4,748,266USD91
2021-01-01 to 2021-03-31-5,151,923USD90
2020-07-01 to 2020-09-30-3,910,124USD92
2020-01-01 to 2020-09-30-9,479,096USD274
2020-04-01 to 2020-06-30-3,484,154USD91
2020-01-01 to 2020-03-31-2,084,818USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-11,181,741USD273
2020-01-01 to 2020-09-30-6,212,413USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-09-30827,615USD273
2020-01-01 to 2020-09-30259,480USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-01-01 to 2021-09-30244,898USD273
2020-07-01 to 2020-09-3016,863USD92
2020-01-01 to 2020-09-30252,420USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-09-3020,182,640USD273
2020-01-01 to 2020-09-3031,886,098USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-827,615USD273
2020-01-01 to 2020-09-305,727,327USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-30-101,869,755USD
At 2020-12-31-88,037,759USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2021-07-01 to 2021-09-3023,095,375shares92
2021-01-01 to 2021-09-3022,731,638shares273
2020-07-01 to 2020-09-3019,801,841shares92
2020-01-01 to 2020-09-3013,958,507shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2021-07-01 to 2021-09-3022,861,051shares92
2021-01-01 to 2021-09-3022,546,634shares273
2020-07-01 to 2020-09-3015,130,685shares92
2020-01-01 to 2020-09-3011,004,733shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-0.17USD/shares92
2021-01-01 to 2021-09-30-0.61USD/shares273
2020-07-01 to 2020-09-30-0.2USD/shares92
2020-01-01 to 2020-09-30-0.68USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-0.21USD/shares92
2021-01-01 to 2021-09-30-0.44USD/shares273
2020-07-01 to 2020-09-30-0.23USD/shares92
2020-01-01 to 2020-09-30-0.51USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-301,513,575USD
At 2020-12-31850,847USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-09-302,185,542USD273
2020-01-01 to 2020-09-301,478,934USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-4,314,545USD92
2021-01-01 to 2021-09-30-14,558,800USD273
2020-07-01 to 2020-09-30-3,914,077USD92
2020-01-01 to 2020-09-30-9,509,431USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-3041,298,245USD
At 2020-12-3133,677,083USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-302,988,292USD
At 2020-12-312,971,282USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-09-300USD
At 2020-12-312,165USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-07-01 to 2021-09-304,314,545USD92
2021-01-01 to 2021-09-3014,803,698USD273
2020-07-01 to 2020-09-303,930,940USD92
2020-01-01 to 2020-09-309,761,851USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-07-01 to 2021-09-302,513,915USD92
2021-01-01 to 2021-09-309,307,512USD273
2020-07-01 to 2020-09-302,629,267USD92
2020-01-01 to 2020-09-305,711,896USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-3024,149,155shares
At 2020-12-3120,577,123shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-09-3040,839,158USD
At 2020-12-3132,665,874USD
At 2020-09-3035,300,340USD
At 2019-12-313,899,328USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-09-302,397,042USD
At 2020-12-311,569,427USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-09-30883,467USD
At 2020-12-31718,580USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2021-09-30278,909USD
At 2020-12-311,011,209USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,931,807USD92
2021-01-01 to 2021-09-30-13,831,996USD273
2020-07-01 to 2020-09-30-3,910,124USD92
2020-01-01 to 2020-09-30-9,478,339USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-301,800,630USD92
2021-01-01 to 2021-09-305,496,186USD273
2020-07-01 to 2020-09-301,301,673USD92
2020-01-01 to 2020-09-304,049,955USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-09-30164,887USD273
2020-01-01 to 2020-09-3098,567USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2021-01-01 to 2021-09-30167,052USD273
2020-01-01 to 2020-09-30101,814USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2021-01-01 to 2021-09-302,165USD273
2020-01-01 to 2020-09-303,247USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-07-01 to 2021-09-30382,738USD92
2021-01-01 to 2021-09-30726,804USD273
2020-07-01 to 2020-09-303,953USD92
2020-01-01 to 2020-09-3030,335USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-09-3020,175,991USD273
2020-01-01 to 2020-09-3025,908,269USD274

Inspect the source

Entity
CAPRICOR THERAPEUTICS, INC. / CIK 0001133869
Captured
2026-09-20T07:41:24.575Z
SEC response SHA-256
b9f947143784aa2a5b7cc0470638338f21bd5664475f1be49c554014f98dbf5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001133869.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))